- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Trastuzumab – March 2019
Trastuzumab: Powder for I.V. infusion 150 mg, Powder for I.V. infusion 440 mg with diluent; Ogivri®
Last updated
5 July 2019